Investors looking for stocks in the Banks - Foreign sector might want to consider either UBS (UBS) or Nu Holdings Ltd. (NU). But which of these two stocks offers value investors a better bang for their buck right now?
UBS plans a $1B loan risk transfer to free up capital as tougher Swiss rules loom following the Credit Suisse collapse.
Melrose Industries PLC (LSE:MRO, OTC:MLSPF) will post a third-quarter trading statement in mid-November with its shares still recovering from the hit to high expectations delivered at its final results in March. Having risen over 20% to around 700p in the first months of the year, following the results, the shares sank below 400p by April.
Does UBS (UBS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Among the largest stocks in Europe, ASML has underperformed its benchmark Euro Stoxx 50 index by around 15% in 2025 so far. That's far enough for UBS which has upgraded the stock to buy on Friday, while bumping up its target price from €660 to €750.
UBS Group stock remains a strong investment, supported by Credit Suisse integration, strategic partnerships, cost efficiencies, and steady NII growth.
Semiconductor stocks are taking a chip out of U.S. indexes to start September—a month that's earned a reputation as the worst for American investors—but for some bulls on Wall Street, that could mean it's time to buy.
UBS (UBS) reported earnings 30 days ago. What's next for the stock?
CNBC's “Closing Bell Overtime” team is joined by John Lovallo, U.S. homebuilders analyst at UBS, to discuss the rally in homebuilder stocks and his market outlook.
Nvidia Corp (NASDAQ:NVDA, ETR:NVD) is set to report its second quarter results amid expectations of robust growth across its data center and compute segments, according to analysts at UBS. Ahead of next week's report, the firm raised its price target to $205 from $175 and maintained a ‘Buy' rating.
Nvidia (NVDA) shares have fallen this week, but one analyst has hiked its price target on the chipmaker ahead of next week's earnings. UBS lifted its target to $205 from $175 while reiterating a buy rating on shares.
CVS Health Corp (NYSE:CVS) has been upgraded by UBS analysts who cited greater confidence in the company's recovery trajectory and multiple levers for earnings growth. The analysts upped their rating to ‘Buy' from ‘Neutral' and raised their price objective to $79 from $67, implying upside from its share price on Monday afternoon of about $70.